Table 1 Baseline characteristics and demographics of the participants (full analysis set).
Characteristics | Tegoprazan 50 mg (n = 36) | Esomeprazole 20 mg (n = 33) |
|---|---|---|
Sex, n (%) | ||
Male | 19 (52.78) | 12 (36.36) |
Female | 17 (47.22) | 21 (63.64) |
Age, mean (SD), years | 56.58 (13.50) | 61.21 (11.96) |
Height, mean (SD), cm | 162.93 (9.39) | 158.66 (8.22) |
Weight, mean (SD), kg | 69.21 (15.53) | 61.89 (8.90) |
Body mass index, mean (SD), kg/m2 | 25.84 (4.09) | 24.53 (2.54) |
Smoking, n (%) | ||
Yes | 6 (16.67) | 0 (0.00) |
No | 30 (83.33) | 33 (100.00) |
Alcohol consumption, n (%) | ||
Yes | 7 (19.44) | 3 (9.09) |
No | 29 (80.56) | 30 (90.91) |
Endoscopic findings, n (%) | ||
Non-erosive | 23 (63.89) | 18 (54.55) |
Erosive (LA-A/B) | 13 (36.11) | 13 (39.39) |
Questionnaire score, mean (SD) | ||
Heartburn frequency score† | 0.56 (0.69) | 0.67 (0.89) |
Regurgitation frequency score† | 0.31 (0.52) | 0.48 (0.97) |
Heartburn severity score†† | 0.50 (0.61) | 0.64 (0.74) |
Regurgitation severity score†† | 0.33 (0.59) | 0.42 (0.79) |
History of PPI use, n (%) | ||
Pantoprazole | 2 (5.56) | 1 (3.03) |
Lansoprazole | 2 (5.56) | 0 (0.00) |
Rabeprazole | 7 (19.44) | 4 (12.12) |
Esomeprazole | 15 (41.67) | 17 (51.52) |
Dexlansoprazole | 2 (5.56) | 3 (9.09) |
Ilaprazole | 8 (22.22) | 6 (18.18) |
P-CAB | 0 (0.00) | 2 (6.06) |
